Summit Therapeutics Inc.
ivonescimab
non-small cell lung cancer (NSCLC)
Resolved
37days ago
Phase 1 readout · May 31, 2026
What's at stake
Phase 1 trial results for ivonescimab in non-small cell lung cancer (NSCLC) are due May 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“According to ASCO, Late-breaking Abstracts are released at 8:00am ET on the day of the presentation, currently scheduled for Sunday, May 31, 2026.”